NCBI PubMed Central
open access
Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors#1113951
- Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era#677239
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer#827648
- Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer#1259280
- Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer#879117
Record · ID 1346654
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive